Early reduction in circulating monocyte count predicts maintenance of remission in patients with rheumatoid arthritis treated with anti-TNF therapy

Ann Rheum Dis. 2021 Dec;80(12):1628-1629. doi: 10.1136/annrheumdis-2021-220642. Epub 2021 Jun 23.

Authors

Muhammad Ruhul Amin Shipa¹, Raj Amarnani², Su-Ann Yeoh¹, M D Mainuddin³, Michael R Ehrenstein⁴

Affiliations

¹ Centre for Rheumatology, Division of Medicine, University College London, London, UK.
² Department of Rheumatology, University College Hospital, London, UK.
³ Department of Rheumatology, North Middlesex University Hospital, London, UK.
⁴ Centre for Rheumatology, Division of Medicine, University College London, London, UK m.ehrenstein@ucl.ac.uk.

PMID: 34162595
DOI: 10.1136/annrheumdis-2021-220642

No abstract available

Keywords: arthritis; methotrexate; rheumatoid; tumour necrosis factor inhibitors.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Arthritis, Rheumatoid / blood*
Arthritis, Rheumatoid / drug therapy*
Arthritis, Rheumatoid / physiopathology
Humans
Leukocyte Count
Maintenance Chemotherapy
Monocytes / cytology*
Prognosis
Remission Induction
Tumor Necrosis Factor Inhibitors / therapeutic use*

Substances

Tumor Necrosis Factor Inhibitors

Grants and funding

20873/VAC_/Versus Arthritis/United Kingdom